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Most breast cancers (approximately 95%), whether in
pre- or post-menopausal women, are initially hormone-
dependent, where the hormone oestradiol (E2) plays a
crucial role in their development and progression. Con-
sequently, processes that modulate the intracellular con-
centrations of active oestrogens can aﬀect the aetiology
of this disease.
Approximately two thirds of breast cancers occur dur-
ing the post-menopausal period when the ovaries have
ceasedtobefunctional.Despitethelowlevelsofcirculating
oestrogens, the tissular concentrationsofoestrone (E1),E2
and their sulphates (E1S;E2S)are several timeshigher than
those found in the plasma or in the area of the breast con-
sidered as normal tissue, suggesting a speciﬁc tumoral bio-
synthesis and accumulation of these hormones [1,2].
There is substantial data that mammary cancer tissue
contains all the enzymes responsible for the local biosyn-
thesis of E2 from circulating precursors. Two principal
pathways are implicated in the last steps of E2 formation
in breast cancer tissues: the aromatase pathway which
transforms androgens into oestrogens [3], and the sul-
phatase pathway which converts E1S into E1 by the oes-
trone–sulphatase [4]. The ﬁnal step of steroidogenesis is
the conversion of the weak E1 to the potent biologically
active E2 by the action of a reductive 17b-hydroxyster-
oid dehydrogenase type 1 activity (17b-HSD-1) [5].
Quantitative evaluation indicates that in human breast
tumours E1S via sulphatase is amuchmore likely precur-
sor for E2 than is androstenedione via aromatase [6,7].
Steroid sulphotransferases (ST), which convert oes-
trogens into their sulphates, are also present in breast
cancer tissues [8]. Fig. 1 gives a general view of oestro-
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photransferases in the uterine endometrium is well doc-
umented. We summarise here recent data concerning the
enzymes involved in the formation and transformation
of oestrogens in these two tissues.2. Anti-sulphatase agents
The anti-oestrogens: tamoxifen, its 4-hydroxy-deriva-
tive, ICI 164,384, various progesterone derivatives (e.g.
medrogestone), retro-progesteronederivatives (e.g. dydro-
gesterone), 19-nor-testosterone derivatives (e.g. norethis-
terone, norelgestromin), 17-hydroxy-nor-progesterone
derivatives (e.g. nomegestrol acetate), 19-nor-progesterone
derivatives (e.g. promegestone), tibolone and its metabo-
lites, diﬀerent synthetic steroidal and non-steroidal com-
pounds, as well as E2 are very active in blocking the
sulphatase activity in breast cancer (for details, see
[9,10]). Fig. 2 provides a comparative study of the sulpha-
tase inhibitory eﬀect of diﬀerent progestins on the conver-
sion of E1S–E2 in hormone-dependent breast cancer cells.3. Anti-17b-hydroxysteroid dehydrogenase agents
The progestins: nomegestrol acetate, medrogestone,
promegestone, dydrogesterone, norelgestromin, as well
as tibolone and its metabolites, are signiﬁcant inhibitors
of 17b-HSD-type 1 in breast cancer cells (for details, see
[9]).4. Control of sulphotransferase activity
As sulphoconjugates are not biologically active, the
control of the formation of these conjugates in breast
cells represents an important mechanism in the modula-
tion of the biological activity in this tissue (for details,
Fig. 2. Comparative eﬀects of various progestins on the inhibition of the oestrone sulphate (E1S) conversion to oestradiol (E2) in the hormone-
dependent T-47D human breast cancer cell line. Preconﬂuent cells were incubated 24 h at 37 C with a physiological concentration (5 · 109 mol/l) of
[3H]-oestrone sulphate (E1S) alone or in the presence of progestins at the concentration of 5 · 107 mol/l. Results (pmol of E2 formed/mg DNA from
E1S) are expressed in percent (%) of control value considered as 100%. The data represent the mean ± standard error of the mean (SEM) of duplicate
determinations of 3–7 independent experiments. Prog., progesterone; Promeg., promegestone; DHD, 20-dihydro-dydrogesterone; Nom. Ac.,
nomegestrol acetate; MPA, medroxyprogesterone acetate; Medro., medrogestone; Noreth., norethisterone; NGMN, norelgestromin. *P 6 0.05 vs.
control value; **P 6 0.01 vs. control value.
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Fig. 1. Enzymatic mechanism involved in the formation and transformation of oestrogens in human breast cancer. The sulphatase pathway (a) is
quantitatively 100–500 times higher than that of the aromatase pathway (b) 17b-HSD-1 = 17b-hydroxysteroid dehydrogenase type 1.
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stone, nomegestrol acetate, promegestone (R-5020), as
well as tibolone and its metabolites, at low concentra-
tions (1 · 109–108M), can stimulate the sulphotransf-
erase activity in diﬀerent breast cancer cells [11,12]. As
an example, Fig. 3 indicates the eﬀects of various pro-
gestins on the sulphotransferase activity in T-47D hor-
mone-dependent breast cancer cells.5. Anti-aromatase agents
Aromatase inhibition by anti-aromatase agents has
shown very positive results in the treatment of pa-
tients with breast cancer. These inhibitors include ste-
roidal and non-steroidal compounds. The most useful
are: aminoglutethimide, 4-hydroxy-androstenedione(Formestane; Lentaron), Vorosole, Letrozole (Fe-
mara), Anastrozole (Arimidex), Examestane (Aro-
masin). A series of Reviews has been published
recently on their biological eﬀects and therapeutic
applications [13–15].6. Control of enzyme activity in the endometrium
The presence of various enzymes involved in the
transformation of oestrogens is well established: sulpha-
tases [16], sulphotransferases [17], and 17b-HSD [18].
However, data on the control of these enzymes in this
tissue are limited. Tseng and Gurpide [19] found 17b-
HSD activity was controlled by progestins, while Falany
and Falany [20] observed a stimulation of sulphotransf-
erases, also by progestins.
Fig. 3. Comparative eﬀects of various progestins on the conversion of
oestrone (E1) to oestrogen sulphates (ES) in the hormone-dependent T-
47D human breast cancer cell line. Preconﬂuent cells were incubated 24
h at 37 C with 5 · 109 mol/l of [3H]-E1 alone or in the presence of
progestins at the concentration of 5 · 109 mol/l. Results (pmol of ES
formed in culture medium per mg DNA from E1) are expressed in
percent (%) of control value considered as 100%. The data represent
the mean ± SEM of duplicate determinations of 3-6 independent
experiments: R-5020, promegestone; Nom. Ac., nomegestrol acetate;
TX-525, a 19-nor progestin of Theramex Laboratories; Medrog.,
medrogestone. *P 6 0.05 vs. control value. **P 6 0.01 vs. control
value.
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Fig. 4. The selective oestrogen enzyme modulator (SEEM) concept in
human hormone-dependent breast cancer cells. The SEEM can control
the enzymatic mechanisms involved in the formation and transforma-
tion of oestrogens in breast cancer cells, where the sulphatase pathway
is quantitatively higher than the aromatase. SEEM-I inhibits the
oestrone sulfatase; SEEM-II the 17b-hydroxysteroid dehydrogenase
type 1; SEEM-III the aromatase activities, and SEEM-IV stimulates
the oestrone sulphotransferase activity. It is suggested that E1S is
present in the tumour outside the cell and reaches the cell membrane
where it is in contact with the intracellular oestrone sulphatase.
ANDR., androgens; E1, oestrone; E2, oestradiol; E1S, oestrone
sulphate.
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More than 15 years of experience have shown that
breast cancer patients treated with the anti-oestrogen,
tamoxifen (e.g. Nolvadex), have a signiﬁcantly reduced
risk of recurrence and an increased overall survival.
However, another way to block oestradiol is by using
anti-enzymes [anti-sulphatase, anti-aromatase, or anti-
17b-hydroxysteroid dehydrogenase (17b-HSD)] which
are involved in oestradiol biosynthesis in breast cancer
tissues. At present, anti-aromatases are extensively used
in breast cancer treatment, with positive beneﬁts. How-
ever, oestrone sulphatase is quantitatively the most
important pathway in oestradiol bioformation in breast
cancer tissue. Very interesting data were obtained con-
cerning the inhibitory activity of various progestins
(promegestone, nomegestrol acetate, medrogestone,
dydrogesterone, norelgestromin), tibolone and its
metabolites, as well as other steroidal and non-steroidal
compounds on oestrone sulphatase, as well as on 17b-
hydroxysteroid dehydrogenase, enzymes involved in
the other pathway of oestradiol formation in breast can-
cer cells. It was also shown that some progestins (pro-
megestone, nomegestrol acetate, medrogestone), as
well as tibolone, can stimulate sulphotransferase activity
in hormone-dependent breast cancer cells. This is an
important point in the physiopathology of this disease,
as it is well known that oestrogen sulphates are biolog-
ically inactive.
The fact that oestradiol (E2) can block its own biofor-
mation in the breast cancer cell provides another aspectto this very complex mechanism in breast cancerisation.
This paradoxical eﬀect of E2 could be related to oestro-
gen replacement therapy (ERT), a treatment that has
been observed to have either no eﬀect or to slightly in-
crease breast cancer incidence [21], but signiﬁcantly de-
creases mortality [22,23].
For these inhibitory or stimulatory eﬀects on the
activity of the enzymes involved in the formation and
transformation of oestrogens in breast cancer, we have
proposed the concept of selective oestrogen enzyme
modulators (SEEM), which is schematically represented
in Fig. 4.
The exploration of various progestins and other sub-
stances in trials on patients with breast or endometrial
cancers, showing an inhibitory eﬀect on sulphatases
and 17b-hydroxysteroid dehydrogenase and a stimula-
tory eﬀect on sulphotransferases, will, in combination
with anti-aromatase agents, provide new possibilities
for the treatment of this disease.References
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